Clinical Trials

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07120698 2026-01-05

CTONG 2508

115 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06837948 2025-02-20

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

160 enrolled

Locally Advanced Non-Small Cell Lung Cancer

NCT06747169 2024-12-27

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

32 enrolled

Squamous Non-Small Cell Lung Cancer SqNSCLC

NCT03872661 2024-12-06

NIBCUN

36 enrolled

Lung Neoplasms

NCT06688656 2024-11-14

Peri-E

Lung Neoplasms

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

45 enrolled

Lung Neoplasms

NCT06620822 2024-10-01

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

296 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04167657 2024-09-19

STAR

Phase 2 Completed

14 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06604351 2024-09-19

Example

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05244213 2024-07-08

NEOTIDE

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06479759 2024-06-28

ACCLAIM

50 enrolled

NSCLC

NCT05004974 2024-03-12

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

NCT04326153 2024-02-01

Neo-Pre-IC

IIIA Stage Non-small Cell Lung Cancer

NCT06221462 2024-01-25

PRIORITY

Carcinoma, Non-Small-Cell Lung

NCT06198907 2024-01-10

JACKPOT33

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Phase 2 Completed

21 enrolled

Lung Neoplasms

NCT04728724 2023-09-13

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03830411 2021-11-08

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

76 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT03863483 2021-11-08

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

70 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04967625 2021-07-28

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

23 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04612673 2020-11-03

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04513301 2020-08-14

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

70 enrolled

Lung Neoplasms

NCT04486287 2020-07-24

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

44 enrolled

Lung Neoplasms

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04252365 2020-02-05

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT04189094 2019-12-06

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

140 enrolled

Lung Neoplasms

NCT04106180 2019-09-26

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

63 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04056949 2019-08-14

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

Small Cell Lung Carcinoma

NCT03874000 2019-03-19

SMART

43 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative